Search - tctmd.com

Displaying 141 - 160 of 295

Sort: Relevancy | Date

High-Intensity Care After Acute HF Pays Off Across LVEF Spectrum: STRONG-HF

News Conference News THT 2023

High-Intensity Care After Acute HF Pays Off Across LVEF Spectrum: STRONG-HF

March 23, 2023

REDUCE LAP-HF II Subanalysis Makes the Case for Invasive Exercise Tests

News Conference News THT 2023

REDUCE LAP-HF II Subanalysis Makes the Case for Invasive Exercise Tests

Yael L. Maxwell

March 22, 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

News Conference News ACC 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

March 14, 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

News Conference News ACC 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

March 09, 2023

STELLAR, ‘Impressive’ Results With Novel Drug Sotatercept in PAH

News Conference News ACC 2023

STELLAR, ‘Impressive’ Results With Novel Drug Sotatercept in PAH

March 06, 2023

BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF

News Conference News ACC 2023

BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF

March 06, 2023

Impact of Heart Failure Management Using Thoracic Fluid Monitoring From A Novel Wearable Sensor: Results of the Benefits of Microcor (μCor™) in Ambulatory Heart Failure (BMAD) Trial

Presentation ACC 2023

Impact of Heart Failure Management Using Thoracic Fluid Monitoring From A Novel Wearable Sensor: Results of the Benefits of Microcor (μCor™) in Ambulatory Heart Failure (BMAD) Trial

Presenter: John P. Boehmer

March 05, 2023

Vast Majority of HFrEF Patients Eligible for Vericiguat

News Daily News

Vast Majority of HFrEF Patients Eligible for Vericiguat

February 08, 2023

Angioedema Risk No Higher With ARNI Than With ACE Inhibitors, ARBs

News Daily News

Angioedema Risk No Higher With ARNI Than With ACE Inhibitors, ARBs

January 23, 2023

Even When Eligible, Not All Acute HF Patients Get GDMT

News Daily News

Even When Eligible, Not All Acute HF Patients Get GDMT

January 11, 2023

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

Query Use of Nontraditional Therapies for HF at Every Visit: AHA Statement

News Daily News

Query Use of Nontraditional Therapies for HF at Every Visit: AHA Statement

December 09, 2022

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says

News Daily News

Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says

December 08, 2022

STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends

News Conference News AHA 2022

STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends

November 07, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

News Conference News AHA 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

November 05, 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

News Conference News AHA 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

Yael L. Maxwell

November 01, 2022

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

News Daily News

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

October 12, 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

News Conference News HFSA 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

October 07, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.